IGF1 and Hyperglycemia: In the present study, the administration of STZ showed significant hyperglycemia, hypoinsulinemia, and significant oxidative stress with a marked increase in the levels of HbA1c, AGEs, cholesterol, TG, LDL, total lipids, urea, uric acid, creatinine, AST, ALT, ALP, bilirubin, CPK, and inflammatory markers including IL-6, TNF-α, and CRP, while C-peptide, HO-1, HDL, albumin, and amylase and growth factors like liver and serum IGF-1 levels markedly decreased.